Portola Pharmaceuticals grant Biogen exclusive, worldwide rights to oral Syk tyrosine kinase (SYK) inhibitors for autoimmune and inflammatory diseases

Portola Pharmaceuticals Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Biogen Idec Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

$28,835.1m on 10/28/2011 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced